O	0	10	Randomized
O	11	16	trial
O	17	19	of
O	20	21	a
B-intervention	22	30	physical
I-intervention	31	39	activity
O	40	52	intervention
O	53	55	in
O	56	61	women
O	62	66	with
O	67	77	metastatic
O	78	84	breast
O	85	91	cancer
O	91	92	.

O	93	101	Exercise
O	102	115	interventions
O	116	123	improve
O	124	131	fitness
O	131	132	,
O	133	143	functional
O	144	152	capacity
O	152	153	,
O	154	157	and
O	158	165	quality
O	166	168	of
O	169	173	life
O	174	176	in
O	177	185	patients
O	186	190	with
O	191	196	early
O	196	197	-
O	197	202	stage
O	203	209	breast
O	210	216	cancer
O	216	217	,
O	218	221	but
O	222	224	to
O	225	228	the
O	229	236	authors
O	236	237	'
O	238	247	knowledge
O	248	253	there
O	254	257	are
O	258	261	few
O	262	266	data
O	267	276	regarding
O	277	280	the
O	281	292	feasibility
O	293	295	or
O	296	305	potential
O	306	314	benefits
O	315	317	of
O	318	326	exercise
O	327	329	in
O	330	335	women
O	336	340	with
O	341	351	metastatic
O	352	358	breast
O	359	365	cancer
O	365	366	.

B-eligibility	367	378	Individuals
I-eligibility	379	383	with
I-eligibility	384	394	metastatic
I-eligibility	395	401	breast
I-eligibility	402	408	cancer
O	409	413	were
O	414	424	randomized
O	425	426	1
O	426	427	:
O	427	428	1
O	429	431	to
O	432	433	a
O	434	436	16
O	436	437	-
O	437	441	week
O	442	450	moderate
O	450	451	-
O	451	460	intensity
O	461	469	exercise
O	470	482	intervention
O	483	485	or
B-control	486	490	wait
I-control	490	491	-
I-control	491	495	list
I-control	496	503	control
I-control	504	509	group
O	509	510	.

O	511	523	Intervention
O	524	529	goals
O	530	538	included
O	539	542	150
O	543	550	minutes
O	551	553	of
O	554	562	moderate
O	562	563	-
O	563	572	intensity
O	573	580	aerobic
O	581	589	exercise
O	590	593	per
O	594	598	week
O	598	599	.

O	600	603	The
O	604	612	baseline
O	613	616	and
O	617	619	16
O	619	620	-
O	620	624	week
O	625	636	evaluations
O	637	645	included
O	646	647	a
O	648	656	modified
O	657	662	Bruce
O	663	667	Ramp
O	668	677	treadmill
O	678	682	test
O	682	683	,
O	684	685	7
O	685	686	-
O	686	689	day
O	690	698	Physical
O	699	707	Activity
O	708	714	Recall
O	715	724	interview
O	724	725	,
O	726	729	and
O	730	738	European
O	739	751	Organization
O	752	755	for
O	756	764	Research
O	765	768	and
O	769	778	Treatment
O	779	781	of
O	782	788	Cancer
O	789	796	Quality
O	797	799	of
O	800	804	Life
O	805	818	Questionnaire
O	819	823	Core
O	824	826	30
O	827	828	(
O	828	833	EORTC
O	834	837	QLQ
O	838	839	C
O	839	840	-
O	840	842	30
O	842	843	)
O	844	857	questionnaire
O	857	858	.

O	859	860	A
O	861	866	total
O	867	869	of
B-total-participants	870	873	101
O	874	886	participants
O	887	891	were
O	892	902	randomized
O	903	904	(
B-intervention-participants	904	906	48
O	907	909	to
O	910	913	the
O	914	926	intervention
O	927	932	group
O	933	936	and
B-control-participants	937	939	53
O	940	942	to
O	943	946	the
O	947	954	control
O	955	960	group
O	960	961	)
O	961	962	.

O	963	966	The
O	967	973	median
O	974	977	age
O	978	980	of
O	981	984	the
O	985	997	participants
O	998	1001	was
B-age	1002	1004	49
I-age	1005	1010	years
O	1010	1011	,
O	1012	1015	the
O	1016	1022	median
O	1023	1027	time
O	1028	1033	since
O	1034	1037	the
O	1038	1047	diagnosis
O	1048	1050	of
O	1051	1061	metastatic
O	1062	1068	breast
O	1069	1075	cancer
O	1076	1079	was
O	1080	1081	1
O	1081	1082	.
O	1082	1083	1
O	1084	1089	years
O	1089	1090	,
O	1091	1094	and
O	1095	1108	approximately
O	1109	1111	42
O	1111	1112	%
O	1113	1115	of
O	1116	1128	participants
O	1129	1133	were
O	1134	1144	undergoing
O	1145	1157	chemotherapy
O	1158	1160	at
O	1161	1164	the
O	1165	1169	time
O	1170	1172	of
O	1173	1183	enrollment
O	1183	1184	.

B-outcome	1185	1190	Study
I-outcome	1191	1200	attrition
O	1201	1204	was
O	1205	1211	higher
O	1212	1214	in
O	1215	1218	the
O	1219	1231	intervention
O	1232	1235	arm
O	1236	1237	(
B-iv-bin-abs	1237	1239	14
O	1240	1252	participants
O	1253	1255	vs
B-cv-bin-abs	1256	1257	8
O	1258	1270	participants
O	1270	1271	;
O	1272	1273	P
O	1274	1275	=
O	1276	1277	.
O	1277	1279	15
O	1279	1280	)
O	1280	1281	.

O	1282	1287	Women
O	1288	1298	randomized
O	1299	1301	to
O	1302	1305	the
O	1306	1314	exercise
O	1315	1327	intervention
O	1328	1339	experienced
O	1340	1341	a
O	1342	1356	nonsignificant
O	1357	1365	increase
O	1366	1370	with
O	1371	1377	regard
O	1378	1380	to
O	1381	1388	minutes
O	1389	1391	of
B-outcome	1392	1398	weekly
I-outcome	1399	1407	exercise
O	1408	1409	(
B-iv-cont-mean	1409	1411	62
I-iv-cont-mean	1411	1412	.
I-iv-cont-mean	1412	1413	4
I-iv-cont-mean	1414	1421	minutes
O	1422	1424	vs
B-cv-cont-mean	1425	1427	46
I-cv-cont-mean	1427	1428	.
I-cv-cont-mean	1428	1429	0
I-cv-cont-mean	1430	1437	minutes
O	1437	1438	;
O	1439	1440	P
O	1441	1442	=
O	1443	1444	.
O	1444	1446	17
O	1446	1447	)
O	1448	1451	and
B-outcome	1452	1460	physical
I-outcome	1461	1472	functioning
O	1473	1474	(
O	1474	1479	EORTC
O	1480	1483	QLQ
O	1484	1487	C30
O	1487	1488	:
B-iv-cont-mean	1489	1490	4
I-iv-cont-mean	1490	1491	.
I-iv-cont-mean	1491	1493	79
O	1494	1496	vs
B-cv-cont-mean	1497	1498	0
I-cv-cont-mean	1498	1499	.
I-cv-cont-mean	1499	1501	93
O	1502	1503	[
O	1503	1504	P
O	1505	1506	=
O	1507	1508	.
O	1508	1510	23
O	1510	1511	]
O	1512	1515	and
B-outcome	1516	1521	Bruce
I-outcome	1522	1526	Ramp
I-outcome	1527	1536	Treadmill
I-outcome	1537	1541	test
O	1541	1542	:
B-iv-cont-mean	1543	1544	0
I-iv-cont-mean	1544	1545	.
I-iv-cont-mean	1545	1547	61
I-iv-cont-mean	1548	1555	minutes
O	1556	1558	vs
B-cv-cont-mean	1559	1560	0
I-cv-cont-mean	1560	1561	.
I-cv-cont-mean	1561	1563	37
I-cv-cont-mean	1564	1571	minutes
O	1572	1573	[
O	1573	1574	P
O	1575	1576	=
O	1577	1578	.
O	1578	1580	35
O	1580	1581	]
O	1581	1582	)
O	1583	1591	compared
O	1592	1596	with
O	1597	1604	control
O	1605	1617	participants
O	1617	1618	.

O	1619	1632	Participation
O	1633	1635	in
O	1636	1638	an
O	1639	1647	exercise
O	1648	1660	intervention
O	1661	1664	did
O	1665	1668	not
O	1669	1675	appear
O	1676	1678	to
O	1679	1685	result
O	1686	1688	in
O	1689	1700	significant
O	1701	1713	improvements
O	1714	1716	in
O	1717	1725	physical
O	1726	1737	functioning
O	1738	1740	in
O	1741	1742	a
O	1743	1756	heterogeneous
O	1757	1762	group
O	1763	1765	of
O	1766	1771	women
O	1772	1778	living
O	1779	1783	with
O	1784	1792	advanced
O	1793	1799	breast
O	1800	1806	cancer
O	1806	1807	.

O	1808	1813	Given
O	1814	1817	the
O	1818	1829	significant
O	1830	1838	benefits
O	1839	1841	of
O	1842	1850	exercise
O	1851	1853	in
O	1854	1859	women
O	1860	1864	with
O	1865	1870	early
O	1870	1871	-
O	1871	1876	stage
O	1877	1883	breast
O	1884	1890	cancer
O	1890	1891	,
O	1892	1896	more
O	1897	1901	work
O	1902	1904	is
O	1905	1911	needed
O	1912	1914	to
O	1915	1922	explore
O	1923	1934	alternative
O	1935	1948	interventions
O	1949	1951	to
O	1952	1961	determine
O	1962	1969	whether
O	1970	1978	exercise
O	1979	1984	could
O	1985	1989	help
O	1990	1995	women
O	1996	2000	with
O	2001	2011	metastatic
O	2012	2019	disease
O	2020	2024	live
O	2025	2029	more
O	2030	2035	fully
O	2036	2040	with
O	2041	2046	fewer
O	2047	2055	symptoms
O	2056	2060	from
O	2061	2068	disease
O	2069	2072	and
O	2073	2082	treatment
O	2082	2083	.
